Clinical Trial Update: Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant dabrafenib (BRAFV600E/K) in surgically resected AJCC Stage IIIC melanoma with BRAFV600E/K mutation has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-05-26